Clinical trial NCT06437392: Evaluation of Sarcopenia and Related Factors in Patients Diagnosed With Psoriatic Arthritis
Official title: Evaluation of Sarcopenia and Related Factors in Patients Diagnosed With Psoriatic Arthritis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Psoriatic Arthritis
Keywords: rheumatic disease
sarcopenia
ultrasonography
Lead sponsor: Ankara City Hospital Bilkent
Sponsor class: OTHER
First posted: 2024-05-31
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients between the ages of 18-65, who were diagnosed with psoriatic arthritis at least one year ago according to the CASPAR criteria, and healthy controls, who visited Ankara Bilkent City Hospital Physical Medicine and Rehabilitation Department, were included.

Brief summary: The purpose of the study is identify the prevalence of sarcopenia and its associated factors in patients with psoriatic arthritis. Furthermore, we aimed to investigate the predictive contribution of USG in diagnosing sarcopenia by assessing the thickness of the rectus femoris, vastus intermedius, and quadriceps muscles in patients with psoriatic arthritis.

Detailed description: After being informed about study and potential risk, all patient and giving written informed consent will undergo screnneing determite eligibility for study entire. Participants who agree to take part in the study and sign the informed consent form will be divided into two groups: patients and healthy volunteers. The patients will undergo a rheumatological examination, and sarcopenia screening will be conducted for both groups. Additionally, the quadriceps muscle thickness of both groups will be measured.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with psoriatic arthritis according to CASPAR criteria at least 1 year ago
* Between 18 and 65 years old
* Normal cognitive functions
* Agrees to participate in the study
* No changes in medical treatment for psoriatic arthritis in the last 3 months

Exclusion Criteria:

* Those with neurological diseases
* Those with hip dysplasia
* Those with upper and lower extremity deformities
* Those with upper and lower extremity joint arthroplasty
* Those with arthritis and deformities in the hands
* Those with lumbar stabilization
* Those with cognitive impairment preventing participation in the study
* Those with body weight beyond the device\&#39;s measurement capacity
* Those who do not agree to participate in the study

Primary outcomes:
measure: Grip strength
timeFrame: 1 day
measure: 4 m gait speed test
timeFrame: 1 day
measure: Quality of life in sarcopenia scale (SARQoL)
timeFrame: 1 day
measure: Tinetti balance and walking test
timeFrame: 1 day
measure: Hospital Anxiety and Depression Scale
timeFrame: 1 day
measure: PSAID12
timeFrame: 1 day
measure: DAS 28
timeFrame: 1 day
measure: BASDAI
timeFrame: 1 day
measure: DAPSA
timeFrame: 1 day
measure: PASI
timeFrame: 1 day
measure: ultrasonography
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Bilkent City Hospital Physical Therapy an Rehabilitation Hospital
state: Bilkent-Cankaya
Study officials:
affiliation: Ankara City Hospital Bilkent
name: Gonca Canan Dogan Tosun, Medical Doctor
role: PRINCIPAL_INVESTIGATOR
affiliation: Ankara City Hospital Bilkent
name: Tuba Güler, Assoc Prof
role: STUDY_DIRECTOR
References:
citation: Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.